Immuno-Biological Laboratories Co (TSE:4570) EBIT : 円125.8 Mil (TTM As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Immuno-Biological Laboratories Co EBIT?

Immuno-Biological Laboratories Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was 円0.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was 円125.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Immuno-Biological Laboratories Co's annualized ROC % for the quarter that ended in Sep. 2024 was 0.00%. Immuno-Biological Laboratories Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Immuno-Biological Laboratories Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 3.08%.

Immuno-Biological Laboratories Co EBIT Historical Data

The historical data trend for Immuno-Biological Laboratories Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuno-Biological Laboratories Co EBIT Chart

Immuno-Biological Laboratories Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

-657.76

-309.88

-249.50

-279.54

125.77

Immuno-Biological Laboratories Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24
EBIT	Get a 7-Day Free Trial															13.01	17.39	-4.55	99.93	-

Competitive Comparison of Immuno-Biological Laboratories Co's EBIT

For the Biotechnology subindustry, Immuno-Biological Laboratories Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuno-Biological Laboratories Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Immuno-Biological Laboratories Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Immuno-Biological Laboratories Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円125.8 Mil.

Immuno-Biological Laboratories Co (TSE:4570) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Immuno-Biological Laboratories Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	0 * ( 1 - 0% )	/	( (874.247	+	902.746)	/ 2 )
=	0	/	888.4965
=	0.00 %

where

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1618.582	-	10.199	-	( 734.136	-	max(0, 257.824	-	1262.12	+	734.136	))
=	874.247

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1645.596	-	12.021	-	( 730.829	-	max(0, 262.302	-	1246.464	+	730.829	))
=	902.746

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Immuno-Biological Laboratories Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	0	/	( ( (135.817 + max(421.581, 0))	+	(167.337 + max(418.461, 0)) )	/	2 )
=	0	/	( ( 557.398	+	585.798 )	/	2 )
=	0	/	571.598
=	0.00 %

where Working Capital is:

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(190.306	+	321.913	+	15.765)	-	(10.199	+	0	+	96.204)
=	421.581

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(178.117	+	321.49	+	16.028)	-	(12.021	+	0	+	85.153)
=	418.461

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Immuno-Biological Laboratories Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	125.774	/	4085.771
	=	3.08 %

Immuno-Biological Laboratories Co EBIT Related Terms

Thank you for viewing the detailed overview of Immuno-Biological Laboratories Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuno-Biological Laboratories Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuno-Biological Laboratories Co Ltd (TSE:4570) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005

Website

http://www.ibl-japan.co.jp

Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.

Immuno-Biological Laboratories Co Headlines

No Headlines